Ask AI
ASH 2025: Key Studies in Leukemias

CE / CME

Conference to Clinic Highlights From the 2025 ASH Annual Meeting: Key Studies in Leukemias

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: February 27, 2026

Expiration: August 26, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Courtney D. Dinardo, MD, MSCE, and Amir T. Fathi, MD, review key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition.

Please note that the key points discussed in this module are illustrated with thumbnails from accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Decera Clinical Education plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those who practice in academic or community settings, please indicate your practice setting:

How many people with leukemia do you provide care for in a typical month?

At ASH 2025, which of the following was reported in the randomized PARADIGM phase II trial comparing azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AML?

When talking to your patient, which of the following would you tell him was reported regarding when most patients achieved a major molecular response (MMR) among those who reached this milestone after receiving second-line therapy with asciminib?